Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories View More Recent Stories
-
POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I (RACA)
-
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
-
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
-
Farallon Urges Toshiba Shareholders to Make Their Voices Heard at Upcoming EGM
-
Form D/A FARALLON CAPITAL OFFSHOR
-
Form D/A Farallon Capital Partner
-
Form D/A Farallon Capital (AM)
-
Form D/A Farallon Capital Institu
-
New Science Ventures Portfolio Company Ventyx Biosciences Raises $114 Million
-
Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs
-
Top Toshiba shareholder gets further support for proposed investigation
-
Glass Lewis Recommends Toshiba Shareholders Vote FOR Farallon Proposal
-
CORRECTING and REPLACING Glass Lewis Recommends Toshiba Shareholders Vote FOR Farallon Proposal
-
BlackRock builds 5% stake in Toshiba, becomes third largest shareholder
-
Farallon Comments on ISS Report Confirming Need for Toshiba to Rebuild Investor Trust
-
Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline
-
Proxy adviser ISS backs shareholder proposal for Toshiba investigation
-
U.S. hedge fund Farallon accuses Toshiba of 'backpedaling' on strategy
-
Farallon Capital Management Issues Letter to Toshiba Shareholders
-
eGenesis Announces $125 Million Series C Financing
-
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
-
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
-
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
-
Top Toshiba shareholder renews call for probe over AGM vote
-
Toshiba says no evidence it pressured Harvard over AGM vote
-
Form 13F-NT Farallon Capital Europe For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
-
Form SC 13G/A AMYRIS, INC. Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Broadmark Realty Capital Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A DermTech, Inc. Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A ENANTA PHARMACEUTICALS Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A PROGENICS PHARMACEUTICAL Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Savara Inc. Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Form SC 13G/A Protagonist Therapeutics Filed by: FARALLON CAPITAL MANAGEMENT LLC
-
Hedge fund Indaba pushes Benefitfocus to put itself up for sale
-
Imago BioSciences to Participate in Upcoming Investor Conferences
-
Orchard Therapeutics Plc (ORTX) Reports $150M Strategic PIPE Financing from 24.12M Share Sale at $6.22/Sh
-
Orchard Therapeutics Announces $150 Million Strategic Financing
-
Orchard Therapeutics Announces $150 Million Strategic Financing
-
Inivata Raises $35 million in Second Close of Series C Financing
-
Imago BioSciences Appoints Enoch Kariuki to Board of Directors
-
BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Signs Agreements to Acquire Leading Digital Musculoskeletal Company, Raise $70 Million Through Private Placement
-
Design Therapeutics Secures $125 Million in Series B Financing to Advance Pipeline of Genomic Medicines for Nucleotide Repeat Expansion Disorders
-
DarioHealth (DRIO) Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing
-
DarioHealth Announces Acquisition of Leading Digital Musculoskeletal Company Upright Technologies and $70 Million Financing
-
Toshiba regains Tokyo exchange's top category amid calls for better governance
-
Rayonier (RYN) Reports Election of Meridee A. Moore and Matthew J. Rivers to Board

